How should dry eye be assessed and managed in a patient receiving a GLP‑1 receptor agonist (e.g., exenatide, liraglutide, dulaglutide, semaglutide)?

Management of Dry Eye in Patients on GLP-1 Receptor Agonists

Assess and manage dry eye in GLP-1 RA users using standard dry eye protocols, as current evidence suggests these medications may actually reduce—rather than cause—dry eye symptoms. The 2024 American Academy of Ophthalmology Dry Eye Syndrome guidelines provide the framework for evaluation and treatment, while emerging research indicates GLP-1 RAs have potential protective effects on the ocular surface 1, 2.

Initial Assessment

When evaluating a patient on GLP-1 RAs (semaglutide, liraglutide, dulaglutide, exenatide, tirzepatide) presenting with dry eye symptoms, conduct a focused evaluation that includes:

History elements specific to this population:

• Duration and timing of GLP-1 RA therapy relative to symptom onset
• Presence of diabetes and glycemic control status (rapid glucose improvement can affect ocular surface)
• Concurrent medications that worsen dry eye (antihistamines, diuretics, antidepressants, beta-blockers) 1
• Digital screen use and environmental factors
• History of diabetic retinopathy (relevant given FDA warnings about retinopathy progression with dulaglutide and liraglutide) 3, 4

Physical examination priorities:

• Tear film meniscus height and tear break-up time
• Meibomian gland assessment (orifice appearance, expressibility, secretion quality)
• Conjunctival and corneal staining patterns with fluorescein and lissamine green
• Eyelid position and closure (periocular volume changes have been reported with GLP-1 RAs, potentially affecting lid-globe mechanics) 5
• Blink completeness and frequency 1

Understanding the GLP-1 RA-Ocular Surface Relationship

The evidence suggests GLP-1 RAs are more likely protective than causative for dry eye. A large Taiwanese population study found GLP-1 RA treatment associated with significantly lower incidence of dry eye disease (aHR 0.853, p=0.0356) and superficial keratitis (aHR 0.670, p=0.0107) compared to diabetic patients not receiving these medications 2. This protective effect was most pronounced in patients under 60 years old.

The proposed mechanism involves anti-inflammatory effects on lacrimal glands, improved tear secretion, enhanced corneal epithelial migration, and corneal nerve regeneration 5. However, pharmacovigilance data show ocular adverse events represent 3.61% of all GLP-1 RA reports, with visual impairment and blurred vision being most common—though these may reflect underlying diabetic eye disease rather than drug causation 6.

Critical nuance: If dry eye symptoms appeared after starting a GLP-1 RA, consider alternative explanations first:

• Rapid glycemic improvement causing temporary osmotic changes
• Gastrointestinal side effects (nausea, vomiting, diarrhea) leading to dehydration and secondary dry eye 3
• Periocular volume loss affecting eyelid support and tear distribution 5

Staged Treatment Approach

Follow the 2024 AAO stepped management protocol 1:

Step 1 (All patients):

• Environmental modification (humidifiers, reduce screen time, avoid direct air flow)
• Preservative-free artificial tears 4-6 times daily
• Warm compresses and eyelid hygiene for meibomian gland dysfunction
• Omega-3 fatty acid supplementation
• Review and modify systemic medications if possible 1

Step 2 (If inadequate response):

• Increase to preservative-free lubricants exclusively
• Punctal occlusion (temporary plugs initially)
• Overnight ointment or moisture chamber devices
• Prescription anti-inflammatory therapy:
  • Cyclosporine 0.05% or 0.09% twice daily
  • Lifitegrast 5% twice daily
  • Short-term topical corticosteroid (loteprednol 0.5% for 2-4 weeks) 1

Step 3 (Moderate to severe cases):

• Autologous serum tears 20-50%
• Oral tetracycline antibiotics (doxycycline 50mg daily) for meibomian gland dysfunction
• Scleral contact lenses for severe cases
• Consider cholinergic agonists (cevimeline 30mg three times daily or pilocarpine 5mg four times daily) for severe aqueous deficiency, though systemic side effects limit use 1

Step 4 (Refractory cases):

• Permanent punctal occlusion
• Amniotic membrane grafts
• Tarsorrhaphy in extreme cases 1

Ophthalmology Referral Criteria

Refer to ophthalmology if any of the following are present:

• Moderate to severe pain
• Lack of response to Step 1-2 therapies after 4-6 weeks
• Corneal infiltration, ulceration, or epithelial defects
• Progressive conjunctival scarring
• Vision loss or significant visual impairment 1

Special Considerations for GLP-1 RA Users

Monitor for diabetic retinopathy progression: FDA labeling for dulaglutide and liraglutide warns that rapid glycemic improvement may temporarily worsen diabetic retinopathy, with higher risk in patients with pre-existing retinopathy (8.5% vs 1% in those without baseline retinopathy for dulaglutide) 3, 4. This is distinct from dry eye but requires concurrent monitoring.

Assess for dehydration: GLP-1 RAs commonly cause nausea, vomiting, and diarrhea. These gastrointestinal effects can lead to dehydration, which secondarily worsens dry eye 3. Ensure adequate hydration and consider anti-emetic therapy if needed.

Evaluate periocular anatomy: Emerging evidence suggests GLP-1 RAs may cause periocular volume loss, brow ptosis, and dermatochalasis, potentially affecting eyelid position and tear film distribution 5. Examine for lagophthalmos, ectropion, or incomplete blink that may require oculoplastic intervention.

Common Pitfalls to Avoid

• Do not automatically attribute dry eye to the GLP-1 RA. The medication is more likely protective than causative based on current evidence 2.
• Do not overlook dehydration from GI side effects as a reversible cause of worsening dry eye symptoms.
• Do not delay ophthalmology referral if corneal staining is present or symptoms are severe—these patients may have underlying diabetic complications requiring specialist management.
• Do not discontinue the GLP-1 RA for mild dry eye alone, given the cardiovascular and metabolic benefits of these medications. Treat the dry eye aggressively with standard protocols first.